Utility of genetic variants to predict prognosis in coronary artery disease patients receiving statin treatment

Abstract

Statins are widely used drugs for lowering low-density lipoprotein cholesterol (LDL-C) and can prevent cardiovascular events. This study aimed to evaluate the influence of single nucleotide polymorphisms (SNPs) and their cumulative effects on the prognosis of coronary artery disease (CAD) patients treated with statins. Sixteen SNPs were genotyped in 785 CAD patients receiving statin therapy, and their associations with clinical features and prognosis of patients were investigated. Four SNPs (rs2296651, rs11206510, rs8192870, and rs1801133) were significantly associated with complications of CAD (P<0.05). Four SNPs (rs8192870, rs4149056, rs12916, and rs2231142) affected blood lipid levels (P<0.05). Furthermore, rs1801133 showed a weak but significant association with fasting plasma glucose (P = 0.033). Survival analyses showed that rs11206510 (adjusted HR = 1.891, 95% CI: 1.188-3.010, P = 0.007) and rs1801133 (adjusted HR = 1.499, 95% CI: 1.141-1.971, P = 0.004) were independently associated with an increased risk of major cardiovascular events, and exhibited cumulative effect on even-free survival (adjusted HR = 1.810, 95% CI: 1.179-2.802, P = 0.007). In conclusion, rs11206510 and rs1801133 were independent risk factors for clinical outcome in CAD patients treated with statins.

Keywords: Statin; coronary artery disease; major cardiovascular event; prognosis.

Figure 1

Cumulative hazard curves for EFS by genotypes. A. rs11206510. B. rs1801133. C. Cumulative effect of unfavorable genotypes of rs11206510 and rs1801133 on OS.